

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Bell <i>et al.</i>	Confirmation No.:	2845
Serial No.:	10/518,679	Filing Date:	August 16, 2005
Patent No.:	7,338,960 B2	Issue Date:	March 4, 2008
Title:	PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS		

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR §1.322**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge any fees or to credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Robert H. Brink
Robert H. Brink
Attorney for Patentee
Registration No. 36,094

Date: 21 May 2008
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-3323
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,338,960 B2

Page 1 of 2

APPLICATION NO. : 10/518,679

ISSUE DATE : March 4, 2008

INVENTOR(S) : Bell *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page:

An inventor's residence in Item (75) should read as follows:

(75) Inventors

-- Romain Luc Marie Gosmini, Les Ulis (FR); --

Item (56) should include additional cited references as follows:

(56) References Cited

-- FOREIGN PATENT DOCUMENTS

EP	1 067 109	1/2001
EP	1 132 376	9/2001
EP	1 283 039	2/2003
WO	97/31907	9/1997
WO	99/11255	3/1999
WO	00/64876	11/2000
WO	01/36351	5/2001 --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GLAXOSMITHKLINE

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,338,960 B2

Page 2 of 2

APPLICATION NO. : 10/518,679

ISSUE DATE : March 4, 2008

INVENTOR(S) : Bell *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

OTHER PUBLICATIONS

-- Gentles, R.G., et al., "Standardization Protocols and Optimized Precursor Sets for the Efficient Application of Automated Parallel Synthesis to Lead Optimization: A Mitsunobu Example," *Journal of Combinatorial Chemistry* (2002), Vol. 4(5), pgs. 442-456.

Kuchar, M., et al., "Benzyloxyarylalipatic Acids: Synthesis and Quantitative Relations between Structure and Antiinflammatory Activity," *Collection of Czechoslovak Chemical Communications*, Academic Press, London, GB, 1982, Vol. 47; pgs. 2514-2524.

Kuchar, M., et al., "The Effects of Lipophilicity on the Inhibition of Denaturation of Serum Albumin and on the Activation of Fibrinolysis Observed with a Series of Benzyloxyarylalipatic Acids," *Collection of Czechoslovak Chemical Communications*, Academic Press, London, GB, 1983, Vol. 48, pgs. 1077-1088. --

In the Claims:

Claim 9 (Column 143, Lines 28-29) should read as follows:

- 9. A compound according to claim 1 wherein X¹ is O or S. --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GLAXOSMITHKLINE

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.